Clinical Trial

Clavulanic Acid for the Treatment of Cocaine Use Disorder

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 2, 2024 (before its estimated July 2024 completion). Its status may not reflect the trial's current state.
Summary
A dose escalation study to assess the efficacy and safety of Clavulanic Acid (CLAV) vs. placebo (PBO) for the treatment of cocaine use disorder (CUD)
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-09-27; most recent amendment 2026-04-29.
Status change: Active, Not Recruiting → Completed 2026-04-29
Status change: Recruiting → Active, Not Recruiting 2024-04-30
Status change: Not Yet Recruiting → Recruiting 2023-04-11
Trial Details
NCT Number NCT05562349
Lead Sponsor Temple University
Collaborators: University of Pennsylvania, Medical University of South Carolina, Research Foundation for Mental Hygiene, Inc.
Conditions Cocaine Dependence
Enrollment 65 participants
Start Date 2023-05-03
Primary Completion 2024-07 (estimated)
Study Completion 2024-07 (estimated)
Updated on ClinicalTrials.gov 2024-05-02